These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36384529)

  • 1. Bone marrow-targetable Green Tea Catechin-Based Micellar Nanocomplex for synergistic therapy of Acute myeloid leukemia.
    Bae KH; Lai F; Mong J; Niibori-Nambu A; Chan KH; Her Z; Osato M; Tan MH; Chen Q; Kurisawa M
    J Nanobiotechnology; 2022 Nov; 20(1):481. PubMed ID: 36384529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-Assembled Daunorubicin/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia.
    Bae KH; Lai F; Oruc B; Osato M; Chen Q; Kurisawa M
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid-green tea catechin micellar nanocomplexes: Fail-safe cisplatin nanomedicine for the treatment of ovarian cancer without off-target toxicity.
    Bae KH; Tan S; Yamashita A; Ang WX; Gao SJ; Wang S; Chung JE; Kurisawa M
    Biomaterials; 2017 Dec; 148():41-53. PubMed ID: 28961534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
    Kumar B; Garcia M; Weng L; Jung X; Murakami JL; Hu X; McDonald T; Lin A; Kumar AR; DiGiusto DL; Stein AS; Pullarkat VA; Hui SK; Carlesso N; Kuo YH; Bhatia R; Marcucci G; Chen CC
    Leukemia; 2018 Mar; 32(3):575-587. PubMed ID: 28816238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-pronged anti-leukemic agent based on a hyaluronic acid-green tea catechin conjugate for inducing targeted cell death and terminal differentiation.
    Liang K; Bae KH; Nambu A; Dutta B; Chung JE; Osato M; Kurisawa M
    Biomater Sci; 2019 Dec; 8(1):497-505. PubMed ID: 31761907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
    Wang A; Zhong H
    Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 11. Carrier-Enhanced Anticancer Efficacy of Sunitinib-Loaded Green Tea-Based Micellar Nanocomplex beyond Tumor-Targeted Delivery.
    Yongvongsoontorn N; Chung JE; Gao SJ; Bae KH; Yamashita A; Tan MH; Ying JY; Kurisawa M
    ACS Nano; 2019 Jul; 13(7):7591-7602. PubMed ID: 31262169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
    Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
    Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia.
    Xu S; Zhang M; Fang X; Meng J; Xing H; Yan D; Liu J; Yang Y; Wen T; Zhang W; Wang J; Wang C; Xu H
    J Hematol Oncol; 2021 Nov; 14(1):193. PubMed ID: 34774070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bone marrow microenvironment - Home of the leukemic blasts.
    Shafat MS; Gnaneswaran B; Bowles KM; Rushworth SA
    Blood Rev; 2017 Sep; 31(5):277-286. PubMed ID: 28318761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases.
    Chandran P; Kavalakatt A; Malarvizhi GL; Vasanthakumari DR; Retnakumari AP; Sidharthan N; Pavithran K; Nair S; Koyakutty M
    Nanomedicine; 2014 May; 10(4):721-32. PubMed ID: 24103301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.
    Kouzi F; Zibara K; Bourgeais J; Picou F; Gallay N; Brossaud J; Dakik H; Roux B; Hamard S; Le Nail LR; Hleihel R; Foucault A; Ravalet N; Rouleux-Bonnin F; Gouilleux F; Mazurier F; Bene MC; Akl H; Gyan E; Domenech J; El-Sabban M; Herault O
    Oncogene; 2020 Feb; 39(6):1198-1212. PubMed ID: 31649334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.
    Pallarès V; Unzueta U; Falgàs A; Aviñó A; Núñez Y; García-León A; Sánchez-García L; Serna N; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Cedó L; Eritja R; Villaverde A; Vázquez E; Casanova I; Mangues R
    Biomaterials; 2022 Jan; 280():121258. PubMed ID: 34847435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment.
    Shafat MS; Oellerich T; Mohr S; Robinson SD; Edwards DR; Marlein CR; Piddock RE; Fenech M; Zaitseva L; Abdul-Aziz A; Turner J; Watkins JA; Lawes M; Bowles KM; Rushworth SA
    Blood; 2017 Mar; 129(10):1320-1332. PubMed ID: 28049638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
    Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
    Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
    Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.